COVID-19

First Evidence that the Antiviral Remdesivir Shows Efficacy in an Animal Model (Rhesus Macaques) of COVID-19

First Evidence that the Antiviral Remdesivir Shows Efficacy in an Animal Model (Rhesus Macaques) of COVID-19

As reported by Brandi Williamson et al. in bioRxiv, remdesivir is the first antiviral treatment with proven efficacy against SARS-CoV-2 in an animal model of COVID-19. This study involving four laboratories from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and the Gilead Sciences, Foster City, CA, USA, indicates […]

Stress, Dyshomeostasis and COVID-19 Mortality: A Big Picture View

Stress, Dyshomeostasis and COVID-19 Mortality: A Big Picture View

Commentary Note that the information contained herein is NOT instructional for medical diagnosis or treatment, see the BrainImmune DISCLAIMER at the end of this article! The pandemic viral illness COVID-19 is especially life-threatening in the elderly and in people with any of a variety of underlying medical conditions. No conceptual framework has been offered as […]

β2-Adrenoceptor-Mediated Upregulation of IL-17 May Contribute to Pulmonary Immunopathology in COVID-19: Does Blockade of IL-17 and β-Adrenergic Effects Hold a Therapeutic Potential?

β2-Adrenoceptor-Mediated Upregulation of IL-17 May Contribute to Pulmonary Immunopathology in COVID-19: Does Blockade of IL-17 and β-Adrenergic Effects Hold a Therapeutic Potential?

Research Hypothesis Note that this is a research hypothesis – the information contained herein is NOT instructional for medical diagnosis or treatment, see the BrainImmune DISCLAIMER at the end of this article! It has been reported that nucleotide-binding oligomerization domain 2 (NOD2) can also function as a cytoplasmic viral pattern recognition receptor (PRR) by triggering […]

Favipiravir (Avigan) Shows Therapeutic Efficacy in Treating Coronavirus in Two Clinical Trials Conducted in China

Favipiravir (Avigan) Shows Therapeutic Efficacy in Treating Coronavirus in Two Clinical Trials Conducted in China

Two recently conducted clinical trials in China involving 340 patients indicate that the Japanese-developed flu drug, Favipiravir, shows therapeutic efficacy in treating COVID-19 infection. The Japanese Fujifilm Toyama Chemical Co. developed Avigan in 2014 and has licensed the patent for Favipiravir to the Chinese company Zhejiang Hisun Pharmaceutical. Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral drug that […]